The prolyl hydroxylase inhibitors (PHIs), which act by stabilizing HIFα to stimulate endogenous EPO production (Figure 2), are promising new agents for treating anemia of chronic kidney disease and perhaps other etiologies165,166. The gene discussed is EPO; the disease is anemia.